MD Anderson and Generate: Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Patients with leptomeningeal metastasis have historically had few treatment options. Now, researchers from The University of Texas MD Anderson Cancer Center have found a combination of targeted therapies, tucatinib and trastuzumab, plus the chemotherapy drug, capecitabine, may improve symptoms and extend survival in some breast cancer patients with LM.

March 27, 2026

Vol.52 No.12

Clinical Roundup

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

Researchers from The University of Texas MD Anderson Cancer Center have found that simultaneously blocking two key “don’t eat me” signals found in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in models of glioblastoma, highlighting a promising strategy.

March 27, 2026

Vol.52 No.12

In Brief

Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon appointed members of MD Anderson’s Allison Institute

Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon were appointed members of the James P. Allison Institute at The University of Texas MD Anderson Cancer Center.

March 06, 2026

Vol.52 No.09

In Brief

“The Journey to End Cancer: From Cause to Cure” exhibit launches national tour, with MD Anderson as presenting sponsor

The University of Texas MD Anderson Cancer Center is launching a science exhibition, showcasing the research, technologies, and new therapies bringing progress in the mission to end cancer.

February 13, 2026

Vol.52 No.06

Clinical Roundup

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

Researchers at The University of Texas MD Anderson Cancer Center have determined that mutations in the KDM6A gene—common in advanced bladder cancer—may serve as a predictive biomarker to determine which patients are less likely to benefit from standard chemotherapy but may respond better to immunotherapy.

January 16, 2026

Vol.52 No.02

Drugs & Targets

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

SOPHiA GENETICS and The University of Texas MD Anderson Cancer Center have entered into a collaboration to accelerate data-driven cancer care through new tools that can accurately analyze, interpret, and translate diagnostic results into clinical practice.

January 09, 2026

Vol.52 No.1

MD Anderson and Generate: Biomedicines enter co-development and commercialization agreement to accelerate novel protein therapeutics for oncology using generative AI

YOU MAY BE INTERESTED IN

Combination treatment benefits patients with leptomeningeal metastases from breast cancer, MD Anderson study finds

Dual-targeting approach improves immunotherapy response in glioblastoma, MD Anderson study finds

Eric Gardner, Betty Kim, Rodrigo Romero, and Hojong Yoon appointed members of MD Anderson’s Allison Institute

“The Journey to End Cancer: From Cause to Cure” exhibit launches national tour, with MD Anderson as presenting sponsor

Mutation predicts chemoresistance and better responses to immunotherapy in advanced bladder cancer, MD Anderson study finds

SOPHiA GENETICS partners with MD Anderson on AI-driven precision oncology

Renew today!

Subscriber content

Never miss an issue!

Login